Abstract
Background: It is known that calcium channel blockers are associated with a risk of gingival hyperplasia. These drugs are widely used in the management of gestational hypertensive disorders.
Case: A 27-year-old G1 woman presented with gingival hyperplasia at 27 weeks gestation during a hospitalisation for preeclampsia. She had been on nifedipine for hypertension for the last 9 weeks. Nifedipine was discontinued and replaced by methyldopa and already after 48 hours the gingival hyperplasia improved. She delivered two weeks later and the gingival hyperplasia resolved completely without surgical intervention. The Naranjo’s score was used to prove the nifedipine’s imputability. Conclusion: This first case report of gingival hyperplasia induced by nifedipine in pregnancy could be used as a reference for clinicians in the management of this adverse effect during the pregnancy.Keywords: Calcium channel blockers, dental management, gingival hyperplasia, nifedipine, preeclampsia, pregnancy.
Current Drug Safety
Title:Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report
Volume: 12 Issue: 1
Author(s): Brochet M.S., Harry M. and Morin F.
Affiliation:
Keywords: Calcium channel blockers, dental management, gingival hyperplasia, nifedipine, preeclampsia, pregnancy.
Abstract: Background: It is known that calcium channel blockers are associated with a risk of gingival hyperplasia. These drugs are widely used in the management of gestational hypertensive disorders.
Case: A 27-year-old G1 woman presented with gingival hyperplasia at 27 weeks gestation during a hospitalisation for preeclampsia. She had been on nifedipine for hypertension for the last 9 weeks. Nifedipine was discontinued and replaced by methyldopa and already after 48 hours the gingival hyperplasia improved. She delivered two weeks later and the gingival hyperplasia resolved completely without surgical intervention. The Naranjo’s score was used to prove the nifedipine’s imputability. Conclusion: This first case report of gingival hyperplasia induced by nifedipine in pregnancy could be used as a reference for clinicians in the management of this adverse effect during the pregnancy.Export Options
About this article
Cite this article as:
M.S. Brochet, M. Harry and F. Morin, Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666160426141851
DOI https://dx.doi.org/10.2174/1574886311666160426141851 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis and Autoimmune Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents D-amino Acids as Novel Blood-based Biomarkers
Current Medicinal Chemistry Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Exploring AT2R and its Polymorphism in Different Diseases: An Approach to Develop AT2R as a Drug Target beyond Hypertension
Current Drug Targets The Role of Antiplatelet Therapy in Primary Prevention. A Review
Current Pharmaceutical Design Endothelial Function and Pathogenesis of Endothelial Dysfunction
Current Immunology Reviews (Discontinued) Epidemiology and Natural History of Patients with NAFLD
Current Pharmaceutical Design Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA
Current Cardiology Reviews Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk
Current Vascular Pharmacology Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Ambulatory Blood Pressure Monitoring in Prehypertensive Subjects
Cardiovascular & Hematological Disorders-Drug Targets PDX-1 and MafA as Potential Therapeutic Targets for Diabetes
Current Signal Transduction Therapy Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design A Refined Framework for Precision and Translational Proteomics in Clinical Research
Current Proteomics The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design